Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)

被引：0
|
作者：
Leal, T. [1 ]
Wakelee, H. [2 ]
Reckamp, K. L. [3 ]
Chiappori, A. [4 ]
Oxnard, G. R. [5 ]
Waqar, S. N. [6 ]
Patel, S. P. [7 ]
Blumenschein, G. R. [8 ]
Neal, J. W. [2 ]
Harrow, K. [9 ]
Holzhausen, A. [9 ]
Selvaggi, G. [9 ]
Zhou, J. [9 ]
Horn, L. [10 ]
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[2] Stanford Univ & Canc Inst, Stanford, CA USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Xcovery Holdings Inc, Palm Beach Gardens, FL USA
[10] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期
关键词：
ALK; NSCLC; ensartinib; CNS;
D O I：
10.1016/j.jtho.2019.09.131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD2.04
引用
收藏
页码：S1171 / S1172
页数：2
相关论文
共 50 条
  • [31] SYSTEMATIC LITERATURE REVIEW (SLR) OF SEQUENCING OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Barrows, S. M.
    Wright, K.
    Copley-Merriman, C.
    Kaye, J. A.
    Chioda, M. D.
    Wiltshire, R.
    Torgersen, K. M.
    Masters, E. T.
    VALUE IN HEALTH, 2018, 21 : S49 - S50
  • [32] Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
    Wang, Li
    Wang, Wen
    ONCOLOGY REPORTS, 2021, 45 (01) : 13 - 28
  • [33] Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)
    Solomon, B.
    Bang, Y. J.
    Camidge, D. R.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [34] Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    De Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H. F.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Tom
    Liu, Geoffrey
    Lolkema, Martijn P.
    Scott, Jeffrey W.
    Yu, Richard
    Selvaggi, Giovanni
    Mishra, Kaushal
    Lau, Yi-Yang Yvonne
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK plus ) non-small cell lung cancer (NSCLC) refractory to alectinib
    Ou, S-H. I.
    Nishio, M.
    Yoshida, T.
    Ahn, M-J.
    Mok, T. S. K.
    Kudou, K.
    Asato, T.
    Yang, H.
    Tong, X.
    Zhang, P.
    Yamamoto, N.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1014 - S1015
  • [36] CNS activity of ensartinib in ALK-positive non-small cell lung cancer patients
    Horn, Leora
    Reckamp, Karen L.
    Patel, Sandip
    Blumenschein, George
    Neal, Joel W.
    Gitlitz, Barbara
    Waqar, Saiama
    Oxnard, Geoffrey
    Brzezniak, Christina
    Dukart, Gary
    Tan, Fenlai
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James
    Wakelee, Heather A.
    CANCER RESEARCH, 2017, 77
  • [37] Cytomorphology of Non-Small Cell Lung Carcinoma (NSCLC) with Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement
    Toll, A. D.
    Illei, P.
    Maleki, Z.
    MODERN PATHOLOGY, 2013, 26 : 104A - 104A
  • [38] BRIGATINIB AS A LEADING OPTION TO MANAGE PREVIOUSLY NOT TREATED PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) IN PORTUGAL
    Monteiro, S.
    Labisa, P.
    Fragoso, J.
    Ferreira, C.
    Cochado, S.
    VALUE IN HEALTH, 2022, 25 (01) : S90 - S90
  • [39] Cytomorphology of Non-Small Cell Lung Carcinoma (NSCLC) with Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement
    Toll, A. D.
    Illei, P.
    Maleki, Z.
    LABORATORY INVESTIGATION, 2013, 93 : 104A - 104A
  • [40] Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial"
    Sullivan, Ivana
    Planchard, David
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1287 - E1292
12345